Stocks:
5,167
ETFs:
2,288
Exchanges:
11
Market Cap:
$62.80T
24h Vol:
$8.65B
Dominance:
MSFT:4.82%
Stocklytics Platform
Instrument logo  GH
Guardant Health
GH
55 / 100
$17.35arrow_drop_up1.10%$0.19

Performance History

Stocklytics logo
Key Stats
Open$16.98
Prev. Close$17.16
EPS-4.28
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$2.14B
PE Ratio-
LOWHIGH
Day Range16.77
17.52
52 Week Range15.81
41.06
Ratios
P/B Ratio14.01
Revenue$563.94M
Operating M. %-73.42%
Earnings$0.00
Earnings Growth %26.76%
EBITDA Margin %-77.37%
ROE %-438.13%
EPS-4.28

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

55vs 55. Market Avg.

All Score 55 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

GHMARKET
Value4239
Quality5440
Ownership4117
Growth3243
Dividends-37
check_circle

Guardant Health 's Price discount from 1 year high of 54.72% is great compared to market average of 18.08%. This indicates GH could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$732.79
24H (%)arrow_drop_up1.09%
24H ($)$7.92
MARKET CAP$695.32B
PRICE$495.25
24H (%)arrow_drop_up0.28%
24H ($)$1.39
MARKET CAP$454.39B
PRICE$146.13
24H (%)arrow_drop_down0.46%
24H ($)-$0.69
MARKET CAP$359.34B
PRICE$131.20
24H (%)arrow_drop_up0.36%
24H ($)$0.48
MARKET CAP$321.39B

About Guardant Health (GH)

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, a suite of advanced analytical technologies to enhance the performance and clinical utility of cancer tests. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. has a research collaboration agreement with the Parker Institute for Cancer Immunotherapy to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across various types of cancer. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Sector
Healthcare
Industry
Diagnostics & Research
CEO
Dr. Helmy Eltoukhy Ph.D.
Headquarters
Palo Alto
Employees
1793
Exchange
NASDAQ
add Guardant Health  to watchlist

Keep an eye on Guardant Health

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Guardant Health 's (GH) price per share?

The current price per share for Guardant Health (GH) is $17.36. The stock has seen a price change of $0.2 recently, indicating a 1.14% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Guardant Health (GH)?

For Guardant Health (GH), the 52-week high is $41.06, which is 136.59% from the current price. The 52-week low is $15.81, the current price is 9.77% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Guardant Health (GH) a growth stock?

Guardant Health (GH) has shown an average price growth of -47.6% over the past three years. It has received a score of 8 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Guardant Health as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Guardant Health (GH) stock price performance year to date (YTD)?

As of the latest data, Guardant Health (GH) has a year-to-date price change of -34.53%. Over the past month, the stock has experienced a price change of 1.31%. Over the last three months, the change has been -23%. Over the past six months, the figure is -34.11%. Looking at a longer horizon, the five-year price change stands at -73.5%.

help
Is Guardant Health (GH) a profitable company?

Guardant Health (GH) has a net income of -$479.45M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 59.74% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -73.42% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $563.95M, with a revenue growth rate of 25.45%, providing insight into the company's sales performance and growth. The gross profit is $336.9M. Operating income is noted at -$562.52M. Furthermore, the EBITDA is -$436.34M.

help
What is the market capitalization of Guardant Health (GH)?

Guardant Health (GH) has a market capitalization of $2.14B. The average daily trading volume is 1.83M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.